natgillin/translations-raw huggingface dataset:
Cyltezo may have a minor influence on your ability to drive, cycle or use machines.
Zdravilo Cyltezo ima lahko blag vpliv na sposobnost vožnje, kolesarjenja ali upravljanja strojev.
Excipients: sodium acetate trihydrate, glacial acetic acid, trehalose dihydrate, polysorbate 80 and water for injections.
Pomožne snovi: natrijev acetat trihidrat, ledocetna kislina, trehaloza dihidrat, polisorbat 80 in voda za injekcije.
If latent tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be consulted.
Če sumite na latentno tuberkulozo, se posvetujte z zdravnikom, ki ima izkušnje z zdravljenjem
After proper training in injection technique, patients may self-inject with Cyltezo if their physician determines that it is appropriate and with medical follow-up as necessary.
Bolniki, ki se naučijo pravilnega postopka injiciranja, si zdravilo Cyltezo lahko injicirajo sami, če zdravnik presodi, da je to primerno, in je zagotovljeno ustrezno medicinsko spremljanje.
Longer term treatment with adalimumab 40 mg weekly for 96 weeks identified no new safety findings.
Daljše, 96-tedensko zdravljenje z adalimumabom 40 mg na teden ni razkrilo novih izsledkov
• Lift pen straight up from skin.
• Peresnik dvignite s kože navpično navzgor.
Neither carcinogenicity studies, nor a standard assessment of fertility and postnatal toxicity, were performed with adalimumab due to the lack of appropriate models for an antibody with limited cross-reactivity to rodent TNF and to the development of neutralising antibodies in rodents.
Z adalimumabom niso bile narejene niti raziskave kancerogenosti, niti standardne ocene plodnosti ter poporodne toksičnosti, in sicer zato, ker ni ustreznih modelov za protitelo z omejeno navzkrižno reaktivnostjo z glodavskim TNF, in zaradi nastanka nevtralizirajočih
Adalimumab concentrations in the synovial fluid from several rheumatoid arthritis patients ranged from 31-96 % of those
Koncentracije adalimumaba v sinovijski tekočini več bolnikov z revmatoidnim artritisom so bile od 31 do 96 % tistih v serumu.
Try not to cover the window with your • Press tip firmly against squeezed injection site.
Okenca ne prekrijte z • Močno pritisnite na stisnjeno mesto injiciranja.
Patients treated with Cyltezo should be given the patient alert card.
Bolniki, ki se zdravijo z zdravilom Cyltezo, morajo dobiti opozorilno kartico za
The primary endpoint in RA study V was the percent of patients who achieved an ACR 50 response at week 52.
Primarni opazovani dogodek študije revmatoidnega artritisa V je bil odstotek bolnikov, ki so do 52. tedna dosegli odziv ACR 50.
Among the 68 patients who flared in the group allocated to treatment withdrawal, 65 completed 12 weeks of rescue therapy with adalimumab, out of which 37 (56.9 %) had regained remission (ASDAS < 1.3) after 12 weeks of restarting the open-label treatment.
Med 68 bolniki iz skupine namenjene prenehanju zdravljenja pri katerih je prišlo do ponovnega zagona bolezni, jih je 65 zaključilo 12 tednov trajajoče rešilno zdravljenje z adalimumabom, od tega jih je 37 (56,9 %) po 12 tednih ponovne odprte faze zdravljenja ponovno doseglo remisijo
Tell your doctor immediately if you get symptoms like changes in your vision, weakness in your arms or legs or numbness or tingling in any part of your body.
Takoj obvestite zdravnika, če dobite simptome, kot so spremembe vida, šibkost rok ali nog ali pa odrevenelost ali mravljinčenje v katerem koli delu
Health-related quality of life and physical function were assessed using the disability index of the Health Assessment Questionnaire (HAQ) in the four original adequate and well-controlled trials, which was a prespecified primary endpoint at week 52 in RA study III.
Z zdravjem povezano kakovost življenja in telesno funkcijo so v štirih originalnih ustreznih in dobro kontroliranih študijah ocenjevali z indeksom invalidnosti z vprašalnikom HAQ (Health Assessment Questionnaire) in je bila v študiji revmatoidnega artritisa III vnaprej določen primarni opazovani dogodek po 52 tednih.
6 months 12 months
8 do 12 let
Concomitant administration of adalimumab with other biologic DMARDS (e.g, anakinra and abatacept) or other TNF-antagonists is not recommended based upon the possible increased risk for infections, including serious infections and other potential pharmacological interactions.
Sočasna uporaba adalimumaba z drugimi biološkimi DMARDS (tj. anakinra in abacept) ali z drugimi antagonisti TNF ni priporočljiva zaradi možnega povečanega tveganja za okužbe, vključno z resnimi okužbami, in drugih potencialnih farmakoloških interakcij (glejte poglavje 4.5).
• You will be instructed by your doctor, nurse or pharmacist on the technique of self-injection.
• O tehniki samoinjiciranja vas bo poučil zdravnik, medicinska sestra ali farmacevt.
Greater improvements at week 12 from baseline compared to placebo were demonstrated in skin-specific health-related quality of life, as measured by the Dermatology Life Quality Index (DLQI; Studies HS-I and HS-II), patient global satisfaction with medication treatment as measured by the Treatment Satisfaction Questionnaire - medication (TSQM; Studies HS-I and HS-II), and physical health as measured by the physical component summary score of the SF-36 (Study HS-I).
Večje izboljšanje v 12. tednu so pokazali glede na izhodiščno vrednost v primerjavi s placebom glede z zdravjem povezane kakovosti življenja, specifične za kožo, merjene z dermatološkim indeksom kakovosti življenja (DLQI, Dermatology life quality index, v študijah HS-I in HS-II), glede bolnikovega splošnega zadovoljstva z zdravljenjem z zdravilom, merjenem z vprašalnikom o zadovoljstvu z zdravljenjem z zdravilom (TSQM, Treatment Satisfaction Questionnaire - medication, v študijah HS-I in HS-II), in glede telesnega zdravja, merjenega s seštevkom telesnih komponent v
Patients induced with 160/80 mg adalimumab achieved clinical remission versus placebo at week 8 in statistically significantly greater percentages in study UC-I (18 % vs. 9 % respectively, p = 0.031) and study UC-II (17 % vs. 9 % respectively, p = 0.019).
Bolniki, ki so za indukcijo dobili 160/80 mg adalimumaba, so 8. teden v primerjavi s placebom dosegli klinično remisijo v statistično značilno večjem odstotku tako v študiji UC-I (18 % v primerjavi z 9 %, p = 0,031) kot v študiji UC-II (17 % v primerjavi z 9 %, p = 0,019).
This study evaluated the efficacy of adalimumab 40 mg every other week/methotrexate combination therapy, adalimumab 40 mg every other week monotherapy and methotrexate monotherapy in reducing the signs and symptoms and rate of progression of joint damage in rheumatoid arthritis for 104 weeks.
Ta študija je ocenila učinkovitost treh shem (kombinirano zdravljenje z adalimumabom 40 mg vsak drugi teden/metotreksatom, monoterapija z adalimumabom 40 mg vsak drugi teden in monoterapija z metotreksatom) za zmanjšanje znakov in simptomov ter hitrosti napredovanja sklepne okvare pri revmatoidnem artritisu v obdobju 104 tednov.
• If you are about to have a surgery or dental procedures, tell your doctor that you are taking Cyltezo.
• Če boste imeli kirurški poseg ali poseg na zobeh, prosimo, obvestite zdravnika, da jemljete zdravilo Cyltezo.
You should record the date when the pen is first removed from refrigerator and the date after which it should
Zapisati si morate datum, ko je bil injekcijski peresnik vzet iz hladilnika in datum, po katerem ga je
Both studies demonstrated an early and sustained effect of adalimumab on the treatment failure rate versus placebo (see
V obeh študijah je bil dokazan zgodnji in vzdrževan učinek adalimumaba na odstotek neuspeha zdravljenja proti placebu (glejte sliko 2).
• If you have mild heart failure and you are being treated with Cyltezo, your heart failure status must be closely monitored by your doctor.
• Če imate blago srčno popuščanje in se zdravite z zdravilom Cyltezo, mora zdravnik natančno nadzorovati stanje vašega srčnega popuščanja.
In a study of 64 patients with rheumatoid arthritis that were treated with adalimumab, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector T-, B-, NK-cells, monocyte/macrophages, and neutrophils.
V študiji 64 bolnikov z revmatoidnim artritisom, zdravljenih z adalimumabom, niso odkrili znakov zavrtja odložene preobčutljivosti, znižanja koncentracije imunoglobulinov ali spremembe števila efektorskih celic T in B, naravnih celic ubijalk, monocitov/makrofagov ali nevtrofilcev.
Your doctor may also prescribe an initial dose of 80 mg which may be administered one week prior to the
Zdravnik lahko predpiše tudi začetni odmerek po 80 mg, ki se ga uporabi en teden pred začetkom
If retreatment with adalimumab is indicated, the above guidance on dose and treatment duration should be followed.
Če je indicirano vnovično zdravljenje z adalimumabom, je treba upoštevati zgoraj navedena navodila
If new areas of damaged skin appear during or after therapy or if existing marks or areas of damage change appearance, tell your doctor.
Če se vam med zdravljenjem ali po njem pojavijo novi predeli poškodb na koži, ali če se vam spremeni videz obstoječih znamenj ali predelov poškodb, morate o tem obvestiti
No other diseasemodifying anti-rheumatic drugs were allowed.
Uporaba drugih imunomodulirajočih zdravil ni bila dovoljena.
Administration of live vaccines (e.g. BCG vaccine) to infants exposed to adalimumab in utero is not recommended for 5 months following the mother's last adalimumab injection during pregnancy.
Uporaba živih cepiv (npr. BCG cepiva) pri dojenčkih, ki so bili izpostavljeni adalimumabu in utero, ni priporočljiva še 5 mesecev po materini zadnji injekciji adalimumaba med nosečnostjo.
Administration of live vaccines (e.g. BCG vaccine) to infants exposed to Cyltezo in utero is not recommended for 5 months following the mother's last Cyltezo injection during pregnancy.
Uporaba živih cepiv (npr. BCG cepiva) pri dojenčkih, ki so bili izpostavljeni zdravilu Cyltezo in utero, ni priporočljiva 5 mesecev po zadnji injekciji zdravila Cyltezo, ki jo je mati prejela med nosečnostjo.
The safety and efficacy of adalimumab were assessed in over 1500 patients with moderately to severely active Crohn's disease (Crohn's Disease Activity Index (CDAI) ≥ 220 and ≤ 450) in randomised, double-blind, placebo-controlled studies.
Varnost in učinkovitost adalimumaba so ocenili pri več kot 1.500 bolnikih z zmerno do zelo aktivno Crohnovo boleznijo (indeks aktivnosti Crohnove bolezni [CDAI] ≥ 220 in ≤ 450) v randomiziranih, dvojno slepih, s placebom kontroliranih študijah.
After two further weeks, continue with a dosage of 40 mg every week or 80 mg every other week, as prescribed by your doctor.
Čez nadaljnja dva tedna nadaljujte z odmerkom 40 mg vsak teden ali 80 mg vsak drugi teden, kot vam bo predpisal zdravnik.
• Inspect Cyltezo pen, medication and expiration date.
• Preverite peresnik zdravila Cyltezo, zdravilo in datum izteka roka uporabnosti.
The primary end point in RA studies I, II and III and the secondary endpoint in RA study IV was the percent of patients who achieved an ACR 20 response at week 24 or 26.
Primarni opazovani dogodek v študijah revmatoidnega artritisa I, II in III ter sekundarni opazovani dogodek v študiji revmatoidnega artritisa IV je bil odstotek bolnikov, ki so po 24 oz. 26 tednih dosegli odziv 20 po ACR.
If a patient develops symptoms suggestive of a lupus-like syndrome following treatment with Cyltezo and is positive for antibodies against double-stranded DNA, further treatment with Cyltezo should not be given (see section
Če se bolniku po zdravljenju z zdravilom Cyltezo pojavijo simptomi, ki nakazujejo lupusu podobni sindrom, in ima pozitivna protitelesa proti dvojnoverižni DNA, zdravljenja z zdravilom Cyltezo ne sme nadaljevati
After 12 weeks of therapy, patients who had received adalimumab in Period A were re-randomised in Period B to 1 of 3 treatment groups (adalimumab 40 mg every week, adalimumab 40 mg every other week, or placebo from week 12 to week 35).
Po 12. tednih terapije so bolnike, ki so prejemali adalimumab v obdobju A, ponovno randomizirali v obdobju B v eno izmed treh skupin zdravljenja (adalimumab 40 mg vsak teden, adalimumab 40 mg vsak drugi teden ali placebo od 12. do 35. tedna).
Kaplan-Meier Curves Summarizing Time to Treatment Failure in the Paediatric
Kaplan-Meier-jeve krivulje povzemajo čas do neuspeha zdravljenja v študiji uveitisa pri pediatričnih bolnikih
The adjusted OR (accounting for baseline differences) was 1.10 (95 % CI 0.45-2.73) with RA and CD combined.
Prilagojeno razmerje obetov (z ozirom na izhodiščne razlike) je bilo 1,10 (95 % interval zaupanja 0,45-2,73) z RA in CB skupaj.
Adalimumab treated patients had significantly greater improvement at week 12 which was maintained through week 24 in both the SF36 and Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL).
Bolniki, ki so dobivali adalimumab, so imeli po 12 tednih značilno večje izboljšanje (ki se je ohranilo do 24. tedna) SF36 in Vprašalnik o kakovosti življenja pri ankilozirajočem spondilitisu (ASQoL, Ankylosing Spondylitis Quality of Life Questionnaire).
Alternatively, if a patient has stopped Cyltezo and signs and symptoms of disease recur, Cyltezo may be readministered.
Če bolnik neha uporabljati zdravilo Cyltezo, pa se znaki in simptomi bolezni ponovijo, je mogoče zdravilo Cyltezo znova uvesti.
Once removed from the refrigerator for room temperature storage, the pen must be used within 14 days or discarded, even if it is returned to the refrigerator.
Ko ga enkrat, namesto v hladilniku, shranjujete pri sobni temperaturi, morate injekcijski peresnik porabiti v 14 dneh ali pa jo zavreči, tudi če jo vrnete v hladilnik.
Cyltezo is a biosimilar medicinal product.
Zdravilo Cyltezo je podobno biološko zdravilo.
Among patients with baseline HS-related skin pain assessment ≥ 3, based on Numeric Rating Scale 0 - 10; 0 = no skin pain, 10 = skin pain as bad as you can imagine
Med bolniki z izhodiščnim rezultatom 3 ali več pri ocenjevanju bolečine, povezane s hidradenitis suppurativa, po numerični ocenjevalni lestvici od 0 do 10; 0 = brez bolečin na koži, 10 = najhujša možna bolečina na koži.
* p value for Standard Dose versus Low Dose comparison.
* p vrednost za primerjavo standardnega odmerka v primerjavi z majhnim odmerkom
A greater proportion of patients on adalimumab had no disease flare during the double-blind period, when compared with those on placebo (70.4 % vs. 47.1 %, p < 0.001) (Figure 1).
Pri večjem deležu bolnikov, ki so prejemali adalimumab, v dvojno slepem obdobju ni prišlo do ponovnega zagona bolezni v primerjavi s tistimi, ki so prejemali placebo (70,4 % v primerjavi s 47,1 %, p < 0,001) (slika 1).
Cyltezo can be taken together with methotrexate or certain disease-modifying anti-rheumatic agents (sulfasalazine, hydroxychloroquine, leflunomide and injectable gold preparations), corticosteroids or pain medications including non-steroidal anti-inflammatory drugs (NSAIDs).
Zdravilo Cyltezo se lahko uporablja skupaj z metotreksatom ali nekaterimi imunomodulirajočimi antirevmatičnimi zdravili (sulfasalazinom, hidroksiklorokinom, leflunomidom in pripravki zlata za injiciranje), kortikosteroidi in zdravili proti bolečinam, vključno z nesteroidnimi protivnetnimi zdravili.
In patients with at least a partial response to adalimumab 40 mg weekly at week 12, the HiSCR rate at week 36 was higher in patients who continued weekly adalimumab than in patients in whom dosing frequency was reduced to every other week, or in whom treatment was withdrawn (see Table 22).
Pri bolnikih z vsaj delnim odzivom na adalimumab v odmerku 40 mg vsak teden v 12. tednu, je bila stopnja kliničnega odziva (HiSCR) v 36. tednu višja pri bolnikih, ki so nadaljevali zdravljenje z adalimumabom vsak teden kot pri bolnikih, pri katerih so pogostnost odmerjanja zmanjšali na vsak drugi teden, ali pri katerih je bilo zdravljenje ukinjeno (glejte preglednico 22).
Vision related effects were not numerically in favour of adalimumab for colour vision in Study UVI and for colour vision, peripheral vision
Učinki povezani z vidom niso bili v korist adalimumaba v primeru barvnega vida v študiji UV I in v primeru barvnega vida, perifernega vida in vida na blizu v študiji UV II.
Ped ACR 30/50/70 responses week 48 significantly greater than those of placebo treated patients p = 0.015
Odzivi "Ped ACR" 30/50/70 so bili 48. teden značilno večji kot pri bolnikih, ki so dobivali placebo
All p-values are pairwise comparisons of proportions for adalimumab versus placebo
Vse vrednosti p so za parne primerjave deležev med adalimumabom in placebom.
The safety of adalimumab in paediatric patients with plaque psoriasis has been assessed for a mean of 13 months.
Varnost adalimumaba pri pediatričnih bolnikih s psoriazo v plakih je bila ocenjena za povprečno
MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO
On rare occasions, a specific and severe type of lymphoma has been observed in patients taking adalimumab.
V redkih primerih so pri bolnikih, ki so dobivali adalimumab, opazili specifično in resno obliko limfoma.
Subjects (n = 215, 54.7 %) who failed to achieve ASAS 20 at weeks 12, or 16 or 20 received early escape open-label adalimumab 40 mg every other week subcutaneously and were subsequently treated as non-responders in the double-blind statistical analyses.
Preiskovanci (n = 215, 54,7 %), ki 12. ali 16. ali 20. teden niso dosegli ASAS 20, so začeli v predčasni odprti fazi dobivati 40 mg adalimumaba vsak drugi teden subkutano, v poznejših statističnih analizah dvojno slepe faza pa so bili obravnavani
Efficacy Responses in Placebo-Controlled AS Study - Study I Reduction of Signs and Symptoms
Preglednica 13: Odzivi učinkovitosti v študiji pri ankilozirajočem spondilitisu, kontrolirani s placebom - študija I Zmanjšanje znakov in simptomov
The other ingredients are sodium acetate trihydrate, glacial acetic acid, trehalose dihydrate, polysorbate 80
Druge sestavine zdravila so natrijev acetat trihidrat, ledocetna kislina, trehaloza dihidrat, polisorbat 80
When needed (for example when you are travelling), a single Cyltezo pre-filled syringe may be stored at room temperature (up to 25°C) for a maximum period of 14 days - be sure to protect it from light.
Če je potrebno (na primer kadar potujete), lahko posamezni napolnjeni injekcijski peresnik zdravila Cyltezo hranite pri sobni temperaturi (do 25 ºC) za največ do 14 dni - zagotovite, da bo zaščitena pred svetlobo.
Taking these results into consideration, Cyltezo is recommended for use in combination with MTX and for use as monotherapy in patients for whom MTX use is not appropriate (see section 4.2).
Z upoštevanjem teh ugotovitev je zdravila Cyltezo priporočljivo uporabljati v kombinaciji z metotreksatom, kot monoterapijo pa pri bolnikih, za katere uporaba metotreksata ni primerna (glejte
A total of 76.5 % (218/285) of patients who entered the retreatment period had a response of PGA “clear” or “minimal” after 16 weeks of retreatment, irrespective of whether they relapsed during withdrawal (69.1 % [123/178] and 88.8 % [95/107] for patients who relapsed and who did not relapse during the withdrawal period, respectively).
Od bolnikov, deležnih ponovnega zdravljenja, jih je skupno 76,5 % (218/285) po 16 tednih ponovnega zdravljenja imelo odziv PGA "čisto" ali "minimalno", ne glede na to, ali je med prenehanjem uporabe prišlo do relapsa (69,1 % [123/178] bolnikov, pri katerih je med prenehanjem uporabe prišlo do relapsa, in 88,8 % [95/107] tistih, pri katerih ni prišlo do relapsa).
Ps Study II (CHAMPION) - Efficacy Results at 16 Weeks MTX N = 110 n (%)
Preglednica 18: Študija pri psoriazi II (CHAMPION) - rezultati učinkovitosti po 16 tednih metotreksat n = 110 n (%)
• including cancer of the lymph system (lymphoma) and
• vključno z rakom limfnega sistema (limfomom) in;
p = 0.027, adalimumab 0.8 mg/kg versus MTX p = 0.083, adalimumab 0.8 mg/kg versus MTX
PASI 75 PGA: čisto/minimalno p = 0,027, adalimumab 0,8 mg/kg v primerjavi z MTX p = 0,083, adalimumab 0,8 mg/kg v primerjavi z MTX
Time to Treatment Failure At or After Week 2 in Study UV II
Čas do neuspeha zdravljenja v ali po 2. tednu v študiji UV II
If something goes wrong with the injection, do not use another Cyltezo pre-filled syringe.
Če injiciranje ne poteka tako, kot bi bilo treba, ne uporabite drugega zdravila Cyltezo napolnjena injekcijska brizga.
Some of these hepatosplenic T-cell lymphomas with adalimumab have occurred in young adult patients on concomitant treatment with azathioprine or 6-mercaptopurine used for inflammatory bowel disease.
Pri uporabi adalimumaba so se nekateri od hepatospleničnih T-celičnih limfomov pojavili pri mladih odraslih bolnikih, ki so se sočasno zdravili z azatioprinom ali 6-merkaptopurinom, ki se uporabljata pri vnetni bolezni črevesa.
Amongst those who responded at week 16 (n = 144), the Pediatric ACR 30/50/70/90 responses were maintained for up to six years in the OLE phase in patients who received adalimumab throughout the study.
Med bolniki, ki so se odzvali 16. teden (n = 144), so se odzivi "Pediatric ACR" 30/50/70/90 v odprti podaljšani fazi ohranili do 6 let pri tistih, ki so ves čas študije dobivali adalimumab.
Kaplan-Meier Curves Summarizing Time to Flare in Study nr-axSpA II
Kaplan-Meier-jeve krivulje povzemajo čas do ponovnega zagona bolezni v študiji nr-axSpA II
Patients who achieved sustained remission for at least 12 weeks (N = 305) (ASDAS < 1.3 at weeks 16, 20, 24, and 28) during the open-label period were then randomised to receive either continued treatment with adalimumab 40 mg eow (N = 152) or placebo (N = 153) for an additional 40 weeks in a double-blind, placebo-controlled period (total study duration 68 weeks).
Bolniki, ki so v odprti fazi dosegli trajno remisijo za vsaj 12 tednov (N = 305) (ASDAS < 1,3 v 16., 20., 24. in 28. tednu), so bili nato randomizirani tako, da so prejemali bodisi nadaljevalno zdravljenje z adalimumabom 40 mg vsak drugi teden (N = 152) ali placebo (N = 153) dodatnih 40 tednov v dvojno slepem, s placebom kontroliranem obdobju (celotno trajanje študije 68 tednov).
It is important that you tell your baby's doctors and other health care professionals about your Cyltezo use during your pregnancy so they can decide when your
Zato je pomembno, da obvestite zdravnika vašega otroka in druge zdravstvene delavce, da ste med nosečnostjo prejemali zdravilo Cyltezo, da se lahko odločijo, kdaj bo vaš otrok lahko prejel katero koli cepivo.
All patients received a 2-week standardised dose of prednisone 60 mg/day at study entry followed by a mandatory taper schedule, with complete corticosteroid discontinuation by
Vsi bolniki so ob začetku študije prejeli 2-tedenski standardizirani odmerek prednizolona 60 mg/dan, čemur je sledil obvezen program postopnega zmanjševanja, s popolno ukinitvijo kortikosteroidov do 15. tedna.
• It is normal to see an air bubble.
• Prisotnost zračnega mehurčka je normalna.
In the pivotal controlled trials in adults and children, the rate of infection was 1.51 per patient year in the adalimumab treated patients and 1.46 per patient year in the placebo and active control-treated patients.
V ključnih kontroliranih preskušanjih pri odraslih in otrocih je bil delež okužb 1,51 na bolnikov-let med bolniki, ki so dobivali adalimumab, in 1,46 na bolnikov-let med bolniki, ki so dobivali placebo oziroma kontrolno učinkovino.
• If you have an infection, including long-term or localised infection (for example, leg ulcer) consult your doctor before starting Cyltezo.
• Če imate kakšno okužbo, vključno z dolgotrajno ali omejeno okužbo (npr. razjedo na nogi), se pred uporabo zdravila Cyltezo posvetujte z zdravnikom.
Usually, Cyltezo is used with methotrexate.
Zdravilo Cyltezo ponavadi uporabljamo z metotreksatom.
the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with
▪ Zdravljenje hudega, aktivnega in progresivnega revmatoidnega artritisa pri odraslih, ki prej še